OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

This multicenter international retrospective analysis aimed to evaluate the efficacy and safety of subcutaneous alemtuzumab (ALZ) as an alternative immunosuppressive therapy for aplastic anemia (AA). The study included 57 with AA patients who received ALZ treatment in four centers in Brazil and the...

ver descrição completa

Detalhes bibliográficos
Main Authors: AR Fonseca, CC Justino, VC Molla, PE Yamakawa, IB Rabelo, A Hill, L Arnold, R Kelly, M Griffin, T Munir, E Velloso, T Dalessandro, AM Risitano, P Scheinberg, A Kulasekararaj, C Arrais-Rodrigues
Formato: Artigo
Idioma:English
Publicado em: Elsevier 2023-10-01
Colecção:Hematology, Transfusion and Cell Therapy
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2531137923002900

Internet

http://www.sciencedirect.com/science/article/pii/S2531137923002900

Registos relacionados